Quick Answer
MYRIAD GENETICS INC reported Stockholders Equity of $368.00 million for fiscal year 2025.
MYRIAD GENETICS INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $368.00M | -47.5% |
| 2024 | $701.10M | -10.5% |
| 2023 | $783.20M | -11.6% |
| 2022 | $885.80M | -8.5% |
| 2021 | $967.80M | +9.9% |
| 2020 | $881.00M | -4.1% |
| 2020 | $918.20M | -15.7% |
| 2019 | $1.09B | +12.7% |
| 2018 | $966.10M | +25.7% |
| 2017 | $768.40M | +3.9% |
| 2016 | $739.60M | +11.8% |
| 2015 | $661.70M | -8.0% |
| 2014 | $719.00M | -1.3% |
| 2013 | $728.60M | +14.6% |
| 2012 | $635.80M | +12.2% |
| 2011 | $566.79M | +1.7% |
| 2010 | $557.58M | +28.4% |
| 2009 | $434.22M | +2.0% |
| 2008 | $425.65M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $372.80M | -49.1% | -3.9% |
| June 30, 2025 | $388.10M | -47.6% | -44.9% |
| March 31, 2025 | $704.90M | -7.2% | +0.5% |
| December 31, 2024 | $701.10M | -10.5% | -4.2% |
| September 30, 2024 | $731.70M | +7.1% | -1.2% |
| June 30, 2024 | $740.50M | +0.7% | -2.6% |
| March 31, 2024 | $760.00M | -9.0% | -3.0% |
| December 31, 2023 | $783.20M | -11.6% | +14.6% |
- MYRIAD GENETICS INC showed a decrease of -47.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, MYRIAD GENETICS INC’s stockholders equity has declined by 13.5% (from $425.65 million to $368.00 million).
- The most recent figure is from MYRIAD GENETICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: